RU2767533C2 - Режим дозирования ингибитора wnt и молекулы антитела к pd-1 в комбинации - Google Patents

Режим дозирования ингибитора wnt и молекулы антитела к pd-1 в комбинации Download PDF

Info

Publication number
RU2767533C2
RU2767533C2 RU2019128843A RU2019128843A RU2767533C2 RU 2767533 C2 RU2767533 C2 RU 2767533C2 RU 2019128843 A RU2019128843 A RU 2019128843A RU 2019128843 A RU2019128843 A RU 2019128843A RU 2767533 C2 RU2767533 C2 RU 2767533C2
Authority
RU
Russia
Prior art keywords
ser
thr
val
leu
pro
Prior art date
Application number
RU2019128843A
Other languages
English (en)
Russian (ru)
Other versions
RU2019128843A3 (enExample
RU2019128843A (ru
Inventor
Джейсон Рассел ДОБСОН
Сьюзан МУДИ
Маргарет Элис МАКЛАФИН
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2019128843A publication Critical patent/RU2019128843A/ru
Publication of RU2019128843A3 publication Critical patent/RU2019128843A3/ru
Application granted granted Critical
Publication of RU2767533C2 publication Critical patent/RU2767533C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
RU2019128843A 2017-02-14 2018-02-12 Режим дозирования ингибитора wnt и молекулы антитела к pd-1 в комбинации RU2767533C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762458640P 2017-02-14 2017-02-14
US62/458,640 2017-02-14
US201862616682P 2018-01-12 2018-01-12
US62/616,682 2018-01-12
PCT/IB2018/050846 WO2018150312A1 (en) 2017-02-14 2018-02-12 Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination

Publications (3)

Publication Number Publication Date
RU2019128843A RU2019128843A (ru) 2021-03-16
RU2019128843A3 RU2019128843A3 (enExample) 2021-05-17
RU2767533C2 true RU2767533C2 (ru) 2022-03-17

Family

ID=61526841

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019128843A RU2767533C2 (ru) 2017-02-14 2018-02-12 Режим дозирования ингибитора wnt и молекулы антитела к pd-1 в комбинации

Country Status (12)

Country Link
US (2) US11406633B2 (enExample)
EP (1) EP3582811B1 (enExample)
JP (3) JP2020506159A (enExample)
KR (2) KR20190112801A (enExample)
CN (2) CN110267682A (enExample)
AU (1) AU2018221557C1 (enExample)
CA (1) CA3051989A1 (enExample)
IL (1) IL268341B2 (enExample)
MX (1) MX2019009630A (enExample)
RU (1) RU2767533C2 (enExample)
TW (1) TWI771372B (enExample)
WO (1) WO2018150312A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
CN108495651A (zh) * 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
BR112021005525A2 (pt) * 2018-09-27 2021-06-29 Musc Foundation For Research Development combinação farmacêutica para o tratamento de câncer
US20220211715A1 (en) * 2019-05-22 2022-07-07 Agency For Science, Technology And Research Pharmaceutical combination
CN113134090B (zh) * 2021-03-26 2022-05-17 武汉大学中南医院 一种抗肿瘤药物组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016196218A1 (en) * 2015-05-31 2016-12-08 Curegenix Corporation Combination compositions for immunotherapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103918C2 (en) 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
US20160303137A1 (en) 2015-04-20 2016-10-20 Indiana University Research And Technology Corporation Dual pi3k and wnt pathway inhibition as a treatment for cancer
CN104767366A (zh) * 2015-04-21 2015-07-08 永济新时速电机电器有限责任公司 辅助变流器和车辆

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016196218A1 (en) * 2015-05-31 2016-12-08 Curegenix Corporation Combination compositions for immunotherapy

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JANKU F. et al. Abstract C45: Phase I study of WNT974, a first-in-class Porcupine inhibitor, in advanced solid tumors // Mol Cancer Ther. 2015. Vol. 14, No. 12 Supplement 2. Abstract C45. *
NAING A. et al. A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors // Journal of Clinical Oncology. 2016. Vol. 34, No. 15_suppl. P. 3060-3060. *
МАШКОВСКИЙ М.Д. Лекарственные средства. - 16-е изд., перераб., испр. и доп. - М.: Новая волна, 2012. - 1216 с. *
Международная статистическая классификация болезней и проблем, связанных со здоровьем. 10 пересмотр (МКБ-10). Том 1 (часть 1). Женева: Всемирная организация здравоохранения, 1995. - 698 с. *
Международная статистическая классификация болезней и проблем, связанных со здоровьем. 10 пересмотр (МКБ-10). Том 1 (часть 1). Женева: Всемирная организация здравоохранения, 1995. - 698 с. МАШКОВСКИЙ М.Д. Лекарственные средства. - 16-е изд., перераб., испр. и доп. - М.: Новая волна, 2012. - 1216 с. ЯКУБКЕ Х.-Д. и др. Аминокислоты, пептиды, белки. - М: Мир, 1985. - 456 с., ил. NAING A. et al. A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors // Journal of Clinical Oncology. 2016. Vol. 34, No. 15_suppl. P. 3060-3060. JANKU F. et al. Abstract C45: Phase I study of WNT974, a first-in-class Porcupine inhibitor, in advanced solid tumors // Mol Cancer Ther. 2015. Vol. 14, No. 12 Supplement 2. Abstract C45. *
ЯКУБКЕ Х.-Д. и др. Аминокислоты, пептиды, белки. - М: Мир, 1985. - 456 с., ил. *

Also Published As

Publication number Publication date
US20230063366A1 (en) 2023-03-02
EP3582811B1 (en) 2024-07-10
AU2018221557A1 (en) 2019-08-15
AU2018221557C1 (en) 2021-10-14
JP2022174157A (ja) 2022-11-22
KR20190112801A (ko) 2019-10-07
WO2018150312A1 (en) 2018-08-23
RU2019128843A3 (enExample) 2021-05-17
TWI771372B (zh) 2022-07-21
IL268341A (en) 2019-09-26
RU2019128843A (ru) 2021-03-16
CN110267682A (zh) 2019-09-20
JP2020506159A (ja) 2020-02-27
TW201836610A (zh) 2018-10-16
CN117752784A (zh) 2024-03-26
KR20240007717A (ko) 2024-01-16
MX2019009630A (es) 2019-11-08
JP2024133495A (ja) 2024-10-02
US20190365746A1 (en) 2019-12-05
AU2018221557B2 (en) 2021-03-11
CA3051989A1 (en) 2018-08-23
IL268341B2 (en) 2023-06-01
EP3582811A1 (en) 2019-12-25
US11406633B2 (en) 2022-08-09

Similar Documents

Publication Publication Date Title
JP7507209B2 (ja) がんを治療するための、ｐｄ－１アンタゴニスト及びｖｅｇｆｒ／ｆｇｆｒ／ｒｅｔチロシンキナーゼ阻害剤の組合せ
AU2017279046B2 (en) Therapeutic uses of a c-Raf inhibitor
EP3423495B1 (en) Antibodies specific to human poliovirus receptor (pvr)
US11001628B2 (en) Combined use of anti PD-1 and anti M-CSF antibodies in the treatment of cancer
JP6767362B2 (ja) リンパ球における阻害経路の中和
US20180177872A1 (en) Combination of PD-1 antagonist with an EGFR inhibitor
AU2018221557B2 (en) Dosing schedule of a Wnt inhibitor and an anti-PD-1 antibody molecule in combination
AU2019240200B2 (en) Pharmaceutical combinations
KR20190107719A (ko) 세리티닙 및 항-pd-1 항체 분자의 조합물에 대한 투여 일정
AU2021260982B2 (en) Dosing regimen for treating a disease modulated by CSF-1R
RU2835316C1 (ru) Режим введения доз для лечения заболевания, модулируемого csf-1r
HK40079353A (en) Antibodies specific to human poliovirus receptor (pvr)
HK40011167A (en) Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination
HK40011167B (en) Dosing schedule of a wnt inhibitor and an anti-pd-1 antibody molecule in combination
HK40001896B (en) Antibodies specific to human poliovirus receptor (pvr)
HK40001896A (en) Antibodies specific to human poliovirus receptor (pvr)